Anavex Life Sciences (STU:12X1) Change In Receivables : €0.94 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Change In Receivables?

Anavex Life Sciences's change in receivables for the quarter that ended in Dec. 2024 was €-0.10 Mil. It means Anavex Life Sciences's Accounts Receivable increased by €0.10 Mil from Sep. 2024 to Dec. 2024 .

Anavex Life Sciences's change in receivables for the fiscal year that ended in Sep. 2024 was €0.23 Mil. It means Anavex Life Sciences's Accounts Receivable declined by €0.23 Mil from Sep. 2023 to Sep. 2024 .

Anavex Life Sciences's Accounts Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Anavex Life Sciences's liquidation value for the three months ended in Dec. 2024 was €102.80 Mil.

Anavex Life Sciences Change In Receivables Historical Data

The historical data trend for Anavex Life Sciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Change In Receivables Chart

Anavex Life Sciences Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Change In Receivables

Get a 7-Day Free Trial

-1.87

-3.64

6.00

0.45

0.23

Anavex Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.77	-0.22	1.92	-0.66	-0.10

Anavex Life Sciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.94 Mil.

Anavex Life Sciences (STU:12X1) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Anavex Life Sciences's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Anavex Life Sciences's accounts receivable are only considered to be worth 75% of book value:

Anavex Life Sciences's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	115.34	-	12.537	+	0.75 * 0	+	0.5 * 0
=	102.80

Anavex Life Sciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AVXL:USA 0HFR:UK 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines